Connor, Clark & Lunn Investment Management (CC&L)’s Ovid Therapeutics OVID Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-11,431
| Closed | -$13.5K | – | 1574 |
|
|
2024
Q3 | $13.5K | Buy |
+11,431
| New | +$13.5K | ﹤0.01% | 1397 |
|
|
2024
Q2 | – | Sell |
-84,233
| Closed | -$257K | – | 1601 |
|
|
2024
Q1 | $257K | Buy |
84,233
+3,058
| +4% | +$9.33K | ﹤0.01% | 1321 |
|
|
2023
Q4 | $261K | Buy |
81,175
+2
| +0% | +$6 | ﹤0.01% | 1205 |
|
|
2023
Q3 | $312K | Buy |
81,173
+11,926
| +17% | +$45.8K | ﹤0.01% | 1128 |
|
|
2023
Q2 | $227K | Buy |
69,247
+38,389
| +124% | +$126K | ﹤0.01% | 1163 |
|
|
2023
Q1 | $79.6K | Sell |
30,858
-9,062
| -23% | -$23.4K | ﹤0.01% | 1170 |
|
|
2022
Q4 | $74.3K | Sell |
39,920
-2,665
| -6% | -$4.96K | ﹤0.01% | 1130 |
|
|
2022
Q3 | $78K | Buy |
42,585
+5,837
| +16% | +$10.7K | ﹤0.01% | 1049 |
|
|
2022
Q2 | $79K | Sell |
36,748
-50,140
| -58% | -$108K | ﹤0.01% | 998 |
|
|
2022
Q1 | $273K | Sell |
86,888
-32,685
| -27% | -$103K | ﹤0.01% | 893 |
|
|
2021
Q4 | $384K | Sell |
119,573
-80,000
| -40% | -$257K | ﹤0.01% | 852 |
|
|
2021
Q3 | $671K | Sell |
199,573
-57,991
| -23% | -$195K | ﹤0.01% | 713 |
|
|
2021
Q2 | $1.01M | Buy |
257,564
+5,800
| +2% | +$22.7K | 0.01% | 671 |
|
|
2021
Q1 | $1.01M | Buy |
251,764
+19,705
| +8% | +$79.2K | 0.01% | 693 |
|
|
2020
Q4 | $536K | Buy |
232,059
+82,070
| +55% | +$190K | ﹤0.01% | 715 |
|
|
2020
Q3 | $861K | Sell |
149,989
-39,978
| -21% | -$229K | 0.01% | 651 |
|
|
2020
Q2 | $1.4M | Buy |
189,967
+31,380
| +20% | +$231K | 0.01% | 534 |
|
|
2020
Q1 | $473K | Buy |
+158,587
| New | +$473K | ﹤0.01% | 704 |
|